Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home

Information for Researchers

Ancillary Studies

TrialNet recognizes the importance of ancillary studies in the overall mission to better understand the Pathway to Prevention (Natural History) of type 1 diabetes, to devise means to prolong the honeymoon phase in subjects with new onset disease, and to prevent diabetes altogether. Ancillary studies that complement the objectives and thereby enhance the value of TrialNet studies are strongly encouraged.

Ancillary studies must be reviewed and approved by TrialNet prior to initiation. Proposals will be evaluated with careful consideration for their potential impact on the objectives and performance of TrialNet studies. Further, ancillary studies must not interfere with the continued interest and participation of the study subjects and investigators. All approved studies will be reviewed yearly to evaluate their progress and impact on TrialNet as a whole.

TrialNet welcomes the submission of ancillary studies as an adjunct to ongoing protocols. A minimum of 4 weeks is required for review. Please refer to the ancillary study policies for application requirements and a description of the review process.

Current Funding Opportunities

TrialNet funding opportunities:

  • Invitation to Negotiate: Mechanistic Analysis of Stored Samples from the TrialNet Immune Effects of Oral Insulin Trial

    Type 1 Diabetes TrialNet intends to award funding to investigators to analyze biosamples from the "Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus" Trial (TN20). Investigators should assemble a team that can design and conduct rigorous and validated assays on samples, and analyze the results jointly with the TrialNet Data Coordinating Center (TNCC) using clinical and other data collected from subjects.

    Letter of Intent (required) due August 3, 2016
    Proposals due September 27, 2016

NIH general announcement for all investigator-initiated research:

Other Biorepository Links:


TN-01 Pathway to Prevention (Natural History)


TN-05 Anti-CD20 (Retuximab)

TN-08 GAD New Onset

TN-09 CTLA-4 Ig (Abatacept)

TN-14 Anti-IL1 Beta (Canakinumab)